Hims & Hers Health (NYSE: HIMS) is surging today. The stock is up 19%, and this is part of a broader 482.5% rally in the past year that has carried this telehealth company to nosebleed levels. Here’s ...

Hims & Hers wants to keep on selling a compounded version of Ozempic. And it's channeling anti-establishment vibes to make its case.

Hims & Hers hit the bullseye with its Super Bowl ad, sparking a surge in clicks to its site.The ad also hit a nerve with the ...

Although Hims’s stock has gone up 65 percent in the past month, investment experts seem split over the reason. Some appear confident in the value of the company’s prospects. Others ...

Nobody really looks forward to reading a Hims ... does, then a compounded version might be for you, or you might opt for a different course of action so that the ED medication doesn’t cover up ...

Shares of Hims & Hers rose 5.2% Monday after the telehealth provider ran an advertisement on Super Bowl Sunday highlighting the company's efforts to fight the obesity epidemic in America.

Hims & Hers makes its Super Bowl commercial debut ... Drug industry groups took issue with the ad in the days leading up to the Super Bowl, asking the Food and Drug Administration to "take action ...

Hims is not simply racking up sales, but also increasingly delivering ... discreet care that insurance often does not cover. The company anticipating as much as $1.465 billion in revenue this ...